Thomas James Doyle serves as Executive at Kura Oncology, Inc., where they oversee executive responsibilities. Since joining the company, Thomas James Doyle has executed 14 insider transactions totaling $154.1K, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 2, 2026 involved receiving (via award) 42,500 shares valued at $0.
Thomas James Doyle currently holds 42,500 shares of Kura Oncology, Inc. (KURA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Thomas James Doyle has been a net seller of KURA stock. They have purchased $0 and sold $154.1K worth of shares.
Thomas James Doyle's most recent insider trade was on Jan 2, 2026, when they sold 42,500 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Nov 14, 2025 | KURA | $50.7K | Sale | 4,539 | $11.18 | Discretionary |
| Nov 13, 2025 | KURA | $0 | Award | 24,967 | $N/A | Discretionary |
| Sep 29, 2025 | KURA | $40.6K | Sale | 4,541 | $8.94 | Discretionary |
| Sep 27, 2025 | KURA | $0 | Award | 24,966 | $N/A | Discretionary |
| Jan 29, 2024 | KURA | $17.1K | Sale | 963 | $17.80 | Discretionary |
| Jan 29, 2024 | KURA | $10.6K | Sale | 594 | $17.80 | Discretionary |
| Jan 29, 2024 | KURA | $13.5K | Sale | 761 | $17.80 | Discretionary |
| Jan 2, 2024 | KURA | $0 | Award | 21,250 | $N/A | Discretionary |
| Feb 16, 2023 | KURA | $0 | Award | 10,625 | $N/A | Discretionary |
| Jan 27, 2023 | KURA | $9.5K | Sale | 682 | $13.89 | Discretionary |
| Jan 27, 2023 | KURA | $12.0K | Sale | 866 | $13.89 | Discretionary |
| Feb 7, 2022 | KURA | $0 | Award | 8,390 | $N/A | Discretionary |